Immuneering Corporation IMRX
Set alert
3.75 USD -0.27 -6.84%
At close · Oct 30
3.75 0.00 0.00%
After hours · Oct 30, 4:00 PM ET
3.72 Day range 4.07
3.42 52-week range 8.33
- YTD
- -43.09%
- 1 year
- -41.58%
- Open
- 4.01
- Prev close
- 4.02
- Mkt cap
- 242.29M
- Vol
- 1.14M
- Avg vol
- 702.74K
- EPS
- -0.93
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 3.72
- High
- 4.07
- Forward P/E
- -1.34
- Beta
- -0.40
- Short ratio
- 1.19
- Inst. own
- 30.11%
- Dividend
- 0.00
- Ex-div date
- Earnings
- Aug 6, 2024
- 50-d avg
- 2.01
- 200-d avg
- 1.84
- 1y target
- 12.42
3M chart
Signals (11)
| Name | Date | Ago |
|---|---|---|
| SMA: Bearish | Oct 30, 2026 | 2 days ago |
| SMA: Bullish | Oct 28, 2026 | 4 days ago |
| MACD: Buy Signal | Oct 20, 2026 | 1 week ago |
| RSI: Oversold | Oct 13, 2026 | 2 weeks ago |
| RSI: Oversold | Oct 6, 2026 | 3 weeks ago |
| SMA: Bearish | Sep 8, 2026 | 1 month ago |
| SMA: Bearish | Sep 4, 2026 | 1 month ago |
| MACD: Sell Signal | Aug 31, 2026 | 2 months ago |
| SMA: Bullish | Aug 11, 2026 | 2 months ago |
| SMA: Bullish | Aug 11, 2026 | 2 months ago |
| MACD: Buy Signal | Aug 6, 2026 | 2 months ago |
Key statistics
- Market cap
- 68.31M
- Enterprise value
- 2.11M
- Trailing P/E
- 0.00
- Forward P/E
- -1.34
- PEG ratio
- 0.00
- Price / sales
- 0.00
- Price / book
- 0.71
- EPS (TTM)
- -1.97
- Beta
- -0.40
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Profit margin
- 0.00%
- Revenue (TTM)
- 0
- Revenue growth
- 0.00%
- Free cash flow
- -31.61M
- Total cash
- 59.73M
- Total debt
- 4.31M
- Return on equity
- -61.81%
- Shares outstanding
- 31.05M
- Short % of float
- 9.27%
- 50-day average
- 2.01
- 200-day average
- 1.84
Analyst view
Consensus: buy
Buy
Price target (mean) 12.42 +231.6% upside
Now 3.75
- Target (low)
- 1.50
- Target (mean)
- 12.42
- Target (high)
- 25.00
Ratings (0m) 7 5 buy · 1 hold · 1 sell
- Strong buy2
- Buy3
- Hold1
- Sell1
- Strong sell0
Next earnings
Aug 6, 2024
Expected Aug 6, 2024. Consensus EPS estimate -0.39167.
Financials — quick view
IMRX Revenue — quarterly 0
IMRX Net income — quarterly -24.19M
IMRX EPS — quarterly -0.37
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Nov 13, 2024 | Sep 1, 2024 | -0.54 | -0.49 | +0.05 | +9.26% |
| Aug 6, 2024 | Jun 1, 2024 | -0.51 | -0.47 | +0.04 | +7.84% |
| Aug 6, 2024 | Jun 1, 2024 | -0.51 | — | — | — |
| May 7, 2024 | Mar 1, 2024 | -0.45 | -0.49 | -0.04 | -8.89% |
| May 7, 2024 | Mar 1, 2024 | -0.45 | — | — | — |
| Mar 1, 2024 | Dec 1, 2023 | -0.48 | — | — | — |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Nov 20, 2024 | Chardan Capital | main | Buy | Buy |
| Nov 14, 2024 | Needham | reit | Buy | Buy |
| Sep 13, 2024 | Needham | reit | Buy | Buy |
| Aug 7, 2024 | Chardan Capital | main | Buy | Buy |
| Aug 7, 2024 | Needham | reit | Buy | Buy |
| May 8, 2024 | Needham | reit | Buy | Buy |
About Immuneering Corporation
Immuneering Corporation, a clinical-stage oncology company, engages in the development of medicines for broad populations of cancer patients. Its lead product candidates include IMM-1-104, a dual-MEK inhibitor currently under Phase 1/2a clinical trial to treat patients with cancer, including pancreatic, melanoma, colorectal, and non-small cell lung cancer caused by mutations of RAS and/or RAF; and IMM-6-415 is in Investigational New Drug application to treat solid tumors. Immuneering Corporation was incorporated in 2008 and is based in Cambridge, Massachusetts.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- Website
- immuneering.com
News
- Immuneering Reports Third Quarter 2026 Financial Results and Provides Business Updates
- Immuneering Presents Design and Methodology of Ongoing Phase 3 MAPKeeper 301 Trial at ESMO Congress 2026
- Immuneering to Present at the 41st Annual Meeting of the Society for Immunotherapy of Cancer (SITC)
- Immuneering Presents Data at 2026 AACR Conference on Pancreatic Cancer Supporting Atebimetinib's Mechanisms Designed to Extend Survival in Pancreatic Cancer
- Immuneering to Present at the ESMO Congress 2026
- Squarepoint Ops LLC Has $288,000 Holdings in Immuneering Corporation $IMRX
- Immuneering To Present Data At American Association For Cancer Research Conference On Pancreatic Cancer: New Frontiers In Biology And Therapeutic Development
- Immuneering to Present at the AACR Conference on Pancreatic Cancer, Highlighting Atebimetinib's Dual Mechanism for Extended Survival
- Immuneering to Participate in Upcoming Investor Conferences
- Immuneering Highlights Atebimetinib’s Potential In 1L Metastatic Pancreatic Cancer As FDA Approves New 2L Treatment
Your note
Sign in to keep a note on IMRX — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| BERMAN ANN E | Director | Purchase | Mar 17, 2024 | 67,465 |
| BOOKMAN MICHAEL | Officer | Stock Award(Grant) | Mar 14, 2024 | 3,850 |
| BRAKEWOOD HAROLD EUGENE | Officer | Purchase | Mar 21, 2024 | 3,900 |
| CORMORANT ASSET MANAGEMENT ,L.P | Beneficial Owner of more than 10% of a Class of Security | Sale | Mar 31, 2024 | 0 |
| FEINBERG PETER | Director | Purchase | Mar 21, 2024 | 1,096,060 |
| HALL BRETT MATTHEW | Officer | Purchase | Mar 19, 2024 | 345,896 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Vanguard Group Inc | 3.45% | 1,070,322 | 2.35M | Sep 29, 2024 |
| Price (T.Rowe) Associates Inc | 2.61% | 810,127 | 1.78M | Sep 29, 2024 |
| Morgan Stanley | 1.45% | 449,311 | 988.48K | Sep 29, 2024 |
| Blackrock Inc. | 1.03% | 318,419 | 700.52K | Sep 29, 2024 |
| Millennium Management Llc | 0.79% | 246,270 | 541.79K | Sep 29, 2024 |
| Geode Capital Management, LLC | 0.68% | 209,641 | 461.21K | Sep 29, 2024 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Vanguard Total Stock Market Index Fund | 2.37% | 736,188 | 1.62M | Sep 29, 2024 |
| Price (T.Rowe) Health Sciences Fund | 1.64% | 509,134 | 1.12M | Sep 29, 2024 |
| Vanguard Extended Market Index Fund | 0.93% | 289,196 | 636.23K | Sep 29, 2024 |
| Fidelity Extended Market Index Fund | 0.38% | 118,328 | 260.32K | Oct 30, 2024 |
| ETF Series Solutions-Range Cancer Therapeutics ETF | 0.21% | 64,035 | 140.88K | Aug 30, 2024 |
| iShares Micro Cap ETF | 0.16% | 49,849 | 109.67K | Oct 30, 2024 |